EVT 201

Drug Profile

EVT 201

Alternative Names: EVT-201

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Evotec AG; Zhejiang Jingxin Pharmaceutical
  • Class Sleep disorder therapies
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 12 Aug 2015 Phase-II development is ongoing in China
  • 31 Dec 2014 Zhejiang Jingxin Pharmaceuticals initiates enrolment in a phase I multi-dose trial in China before December 2014
  • 12 Nov 2014 Phase-II clinical trials in Insomnia in China (PO) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top